OncologyImmuno-oncologyImmunology & inflammation QSPTCE/BsAb

CD3×5T4 In Vitro Activation and Cytotoxicity QSP

Reference paper ↗

Fixed-effect in vitro model linking CD3×5T4 immune-synapse formation to T-cell activation, differentiation, and delayed tumor-cell killing.

Therapeutic
DuoBody-CD3x5T4, bsIgG1-CD3x5T4
Modality
Bispecific antibody / T-cell engager
Target
CD3, 5T4
Disease
In vitro solid-tumor cell-line assay (not disease-specific)
Model type
QSP, TCE/BsAb

Complete model workspace

Checking workspace access…

Parameters
33
States
17
Equations
17
Derived outputs
18

Explore this model

Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.

MDA-MB-468 untreated, E:T 4:1

Null-control culture with 16,000 tumor cells and 64,000 resting T cells, matching the referenced assay setup.

Starting result

This result reflects the starting settings. Run your changes to update it.

Result preview could not load

The generated result could not be loaded. The inputs remain available below.

Starting configuration

Time: 0–72 hour; step 1

InputDefaultAvailable range
CD3-arm 3D dissociation constant683 nM341.5–1,025 nM
Trimer threshold for half-maximal activation2.13 molecule/cell1.065–3.195 molecule/cell
Maximum T-cell activation rate0.0106 1/hr0.0053–0.0159 1/hr
Aggregate trimer threshold for half-maximal killing7,098 molecule3,549–1.06e+4 molecule
Maximum per-effector tumor killing rate1.30e-5 1/(hour*cell)6.50e-6–1.95e-5 1/(hour*cell)

Expected readouts

Immune-synapse trimers per T cell (trimers/T cell) · Activated or effector T cells (%) · Effector T cells (cells/well) · Tumor-cell cytotoxicity (%) · Viable and apoptotic tumor cells (cells/well)

Adjustable model parameters

This public explorer exposes 5 curated parameters. Sign in to edit all 33 declared model parameters.

More key parameters (1)

How the model represents the biology

Links per-cell CD3×5T4 trimer formation to resting-to-activated-to-effector T-cell dynamics and three-stage apoptotic tumor-cell loss across drug affinity, concentration, antigen density, and effector-to-target ratio.

A CD3×5T4 bispecific antibody bridges a resting T cell and a 5T4-positive tumor cell. Per-cell trimers activate and expand T cells, which differentiate into effectors. Effector cells push proliferating tumor cells through three apoptotic transit stages, producing activation and cytotoxicity readouts.
Found a scientific issue? Email helpdesk@unibiointelligence.com with model ID yuan_2026_cd3x5t4_in_vitro_qsp.

Research use only — not for patient-specific prediction or dosing advice.

Ubi Biologics